Supervisory Board

Prof. Dr. Friedl
Since 1991, Prof. Dr. Peter Friedl has been Professor of Biotechnology at the Technical University of Darmstadt with key activities in cell culture technology and endothelial cell biology and an emphasis on the regulation of mechanosensitive apoptosis in endothelial cells and fibroblasts. Previously, Prof. Friedl was a professor of biotechnology at the TFH Berlin. After studying biology, he completed his doctoral thesis at the Max- Planck- Institute (MPI) for Biology in Tübingen and at the Society for Biotechnology in Braunschweig (GBF).

Mr. Matthias Hoffmann
Diplom-Kaufmann Matthias Hoffmann is a partner in the law firm BENKERT + PARTNER in Frankfurt on the Main and has extensive knowledge of the national and international accounting. He performs annual financial audits, reviews, and comprehensive advisory services in connection with transactions. He studied Business Administration and is a Chartered Accountant with previous working experience at Arthur Andersen and Ernst & Young.

Heiner Hoppmann
Heiner Hoppmann was founder and CEO of Aenova Group until 2015. He has more than 30 years of industry experience in senior and top management positions at Hoechst, Schering, Ratiopharm, Siegfried, and Aenova Group. Under his leadership, Aenova grew within seven years from a 200 Mio. € mid-sized CMO to the Europe's leading CDMOs with more than 750 Mio. € in sales, making it the global number 3 in the CDMO industry. His broad expertise covers all areas of the pharmaceutical value chain, from strategy and corporate development (including M&A and finance) to business development and operations (including R&D, supply chain management, sourcing and manufacturing). Heiner Hoppmann is a pharmacist by training. Since founding Fidelio Healthcare Partners, he has supported a significant number of transactions as senior advisor and consultant for various investment funds, and has been working closely with a series of mid-sized pharma companies on strategic transformation projects.

Dr. Manfred May
Dr. Manfred May has over 30 years of international management experience and is highly renowned and respected in the international pharmaceutical industry. He is Managing Director of Dr. May Pharma Consult GmbH, where he advises pharmaceutical corporations in the areas of mergers, acquisitions, licensing, joint ventures and market entry strategies worldwide. From 1993 to 1996, Dr. May was a board member of the pharmaceutical company, Celesio AG, Stuttgart. Previously, he worked at Merck KGaA as Managing Director of pharmaceuticals in Brazil and then Latin America and Southern Europe, followed by the responsibility for Merck KGaA’s worldwide operative pharmaceutical business.

Dr. Bernhard Seehaus
Dr. Bernhard Seehaus is German and European Patent Attorney and has been working as Associate General Patent Counsel in the department of Patent Pharmaceuticals at Merck KGaA since 2005. His main areas of activity are licensing of key technologies, technology assessments and projects in the areas of business development and M & A. Holding a PhD in biology, Dr. Seehaus gained extensive experience in advising start-up companies in the life sciences when he was co-founder of the biotechnology service provider Genius GmbH (now Genius Biotechnologie GmbH).

Dr. Rüdiger Weseloh
Dr. Rüdiger Weseloh has been a Senior Director at Merck Serono since 2010, and there he heads the department for strategic transactions and leads the negotiations for the acquisition of licences for new active substance candidates. Previously, Dr. Weseloh, who studied biochemistry and obtained a doctorate as a neuroscientist, had worked as an equity analyst for two private banks in Frankfurt and Cologne.